Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1979 Dec;64(6):1669–1680. doi: 10.1172/JCI109629

Metabolic clearance and production rates of prolactin in man.

D S Cooper, E C Ridgway, B Kliman, R N Kjellberg, F Maloof
PMCID: PMC371321  PMID: 583048

Abstract

Metabolic clearance rates (MCR) and production rates (PR) of prolactin (PRL) have been determined by the constant infusion to equilibrium technique in 11 normal subjects, 6 patients with hyperthyroidism, 4 patients with hypothyroidism, and 9 patients with hyperprolactinemia. PRL MCR was also determined tin four patients during dopamine infusion. Mean PRL MCR was 46 +/- 1 ml/min per m2 in women and 44 +/- 3 ml/min per m2 in men, and was significantly correlated with body mass (r = 0.84, P less than 0.001). In contrast with controls, PRL MCR was higher in hyperthyroidism (MCR = 52 +/- 8 ml/min per m2, P less than 0.05), was slightly lower in hypothyroidism (MCR = 38 +/- 10 ml/min per m2, P = NS), and was significantly correlated with serum thyroxine (r = 0.46, P less than 0.02). PRL MCR was lower than controls in hyperprolactinemia (MCR = 40 +/- 5 ml/min per m2, P less than 0.01) and was inversely correlated with serum PRL (r = -0.72, P less than 0.001). PRL MCR was not significantly changed by dopamine infusion. Mean PRL PR for women and men was 211 +/- 74 and 187 +/- 44 micrograms/d per m2, respectively (P = NS). In hyperthyroidism the PRL PR was elevated (PR = 335 +/- 68 micrograms/d per m2, P less than 0.02), but in hypothyroidism the increase (PR = 233 +/- 159 micrograms/d per m2) was not significant. In hyperprolactinemia the PRL PR was extremely high (PR = 31,000 +/- 29,000 micrograms/d per m2). Dopamine infusion decreased RPL PR from 270 to 66 micrograms/d per m2 indicating that its effect was on pituitary PRL secretion and not PRL metabolism. To evaluate possible circulating PRL heterogeneity that might arise during infusion, gel filtration of infusate and serum obtained during the MCR procedure was performed. Labeled monomeric PRL (peak III, Kav (partition coefficient) = 0.4) was partially converted to two larger forms (peaks I and II) in vivo. Peak I (Kav = 0) was 30--40% immunoprecipitable, although peak II (Kav = 0.2) was not immunoprecipitable. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of peak I resulted in greater than or equal to 90% conversion to peak III and restoration of full immunoactivity. Thus, peak I is a noncovalently linked aggregate that is partially immunoactive, and therefore able to alter MCR determinations. These studies demonstrate the impact of hormone heterogeneity on MCR estimations and suggest that gel filtration of immunoprecipitable material be an integral part of future MCR measurements.

Full text

PDF
1669

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beitins I. Z., Rattazzi M. C., MacGillivray M. H. Conversion of radiolabeled human growth hormone into higher molecular weight moieties in human plasma in vivo and in vitro. Endocrinology. 1977 Aug;101(2):350–359. doi: 10.1210/endo-101-2-350. [DOI] [PubMed] [Google Scholar]
  2. Besses G. S., Burrow G. N., Spaulding S. W., Donabedian R. K. Dopamine infusion acutely inhibits the TSH and prolactin response to TRH. J Clin Endocrinol Metab. 1975 Nov;41(5):985–988. doi: 10.1210/jcem-41-5-985. [DOI] [PubMed] [Google Scholar]
  3. Bigos S. T., Ridgway E. C., Kourides I. A., Maloof F. Spectrum of pituitary alterations with mild and severe thyroid impairment. J Clin Endocrinol Metab. 1978 Feb;46(2):317–325. doi: 10.1210/jcem-46-2-317. [DOI] [PubMed] [Google Scholar]
  4. Birge C. A., Jacobs L. S., Hammer C. T., Daughaday W. H. Catecholamine inhibition of prolactin secretion by isolated rat adenohypophyses. Endocrinology. 1970 Jan;86(1):120–130. doi: 10.1210/endo-86-1-120. [DOI] [PubMed] [Google Scholar]
  5. Cameron D. P., Burger H. G., Catt K. J., Doig A. Metabolic clearance rate of radioiodinated human growth hormone in man. J Clin Invest. 1969 Sep;48(9):1600–1608. doi: 10.1172/JCI106125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Chen H. T., Lu K. H., Meites J. Effects of hypo- and hyperthyroidism on 5-hydroxytriptophan and chlorpromazine- induced prolactin release in the rat. Proc Soc Exp Biol Med. 1976 Apr;151(4):739–741. doi: 10.3181/00379727-151-39297. [DOI] [PubMed] [Google Scholar]
  7. Chopra I. J., Abraham G. E., Chopra U., Solomon D. H., Odell W. D. Alterations in circulating estradiol-17 in male patients with Graves's disease. N Engl J Med. 1972 Jan 20;286(3):124–129. doi: 10.1056/NEJM197201202860303. [DOI] [PubMed] [Google Scholar]
  8. Chopra I. J. Gonadal steroids and gonadotropins in hyperthyroidism. Med Clin North Am. 1975 Sep;59(5):1109–1121. doi: 10.1016/s0025-7125(16)31961-7. [DOI] [PubMed] [Google Scholar]
  9. Coble Y. D., Jr, Kohler P. O., Cargille C. M., Ross G. T. Production rates and metabolic clearance rates of human follicle-stimulating hormone in premenopausal and postmenopausal women. J Clin Invest. 1969 Feb;48(2):359–363. doi: 10.1172/JCI105992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Davis S. L., Borger M. L. Metabolic clearance rates and secretion rates of prolactin in sheep. Endocrinology. 1973 May;92(5):1414–1418. doi: 10.1210/endo-92-5-1414. [DOI] [PubMed] [Google Scholar]
  11. Davis S. L., Borger M. L. The effect of thyroidectomy on the secretion of prolactin and on plasma levels of thyrotropin, luteinizing hormone and growth hormone in lambs. Endocrinology. 1973 Jun;92(6):1736–1739. doi: 10.1210/endo-92-6-1736. [DOI] [PubMed] [Google Scholar]
  12. Delitala G., Masala A., Alagna S., Devilla L. Plasma prolactin response to L-dopa TRH and metaclopramide in thyrotoxicosis. Biomedicine. 1976 Jul;25(5):173–176. [PubMed] [Google Scholar]
  13. Diefenbach W. P., Carmel P. W., Frantz A. G., Ferin M. Suppression of prolactin secretion by L-dopa in the stalk-sectioned rhesus monkey. J Clin Endocrinol Metab. 1976 Sep;43(3):638–642. doi: 10.1210/jcem-43-3-638. [DOI] [PubMed] [Google Scholar]
  14. Fang V. S., Kim M. H. Study on maternal, fetal, and amniotic human prolactin at term. J Clin Endocrinol Metab. 1975 Dec;41(06):1030–1034. doi: 10.1210/jcem-41-6-1030. [DOI] [PubMed] [Google Scholar]
  15. Fang V. S., Refetoff S. Heterogeneous human prolactin from a giant pituitary tumor in a patient with panhypopituitarism. J Clin Endocrinol Metab. 1978 Oct;47(4):780–787. doi: 10.1210/jcem-47-4-780. [DOI] [PubMed] [Google Scholar]
  16. Garnier P. E., Aubert M. L., Kaplan S. L., Grumbach M. M. Heterogeneity of pituitary and plasma prolactin in man: decreased affinity of "Big" prolactin in a radioreceptor assay and evidence for its secretion. J Clin Endocrinol Metab. 1978 Dec;47(6):1273–1281. doi: 10.1210/jcem-47-6-1273. [DOI] [PubMed] [Google Scholar]
  17. Gautvik K. M., Tashjian A. H., Jr, Kourides I. A., Weintraub B. D., Graeber C. T., Maloof F., Suzuki K., Zuckerman J. E. Thyrotropin-releasing hormone is not the sole physiologic mediator of prolactin release during suckling. N Engl J Med. 1974 May 23;290(21):1162–1165. doi: 10.1056/NEJM197405232902103. [DOI] [PubMed] [Google Scholar]
  18. Guyda J. H. Heterogeneity of human growth hormone and prolactin secreted in vitro: Immunoassay and radioreceptor assay correlations. J Clin Endocrinol Metab. 1975 Nov;41(5):953–967. doi: 10.1210/jcem-41-5-953. [DOI] [PubMed] [Google Scholar]
  19. Honbo K. S., van Herle A. J., Kellett K. A. Serum prolactin levels in untreated primary hypothyroidism. Am J Med. 1978 May;64(5):782–787. doi: 10.1016/0002-9343(78)90517-x. [DOI] [PubMed] [Google Scholar]
  20. Kiefer K. A., Malarkey W. B. Size heterogeneity of human prolactin in CSF and serum: experimental conditions that alter gel filtration patterns. J Clin Endocrinol Metab. 1978 Jan;46(1):119–124. doi: 10.1210/jcem-46-1-119. [DOI] [PubMed] [Google Scholar]
  21. Koch Y., Chow Y. F., Meites J. Metabolic clearance and secretion rates of prolactin in the rat. Endocrinology. 1971 Nov;89(5):1303–1308. doi: 10.1210/endo-89-5-1303. [DOI] [PubMed] [Google Scholar]
  22. Kohler P. O., Ross G. T., Odell W. D. Metabolic clearance and production rates of human luteinizing hormone in pre- and postmenopausal women. J Clin Invest. 1968 Jan;47(1):38–47. doi: 10.1172/JCI105713. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Kourides I. A., Re R. N., Weintraub B. D., Ridgway E. C., Maloof F. Metabolic clearance and secretion rates of subunits of human thyrotropin. J Clin Invest. 1977 Mar;59(3):508–516. doi: 10.1172/JCI108666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Lieberman M. E., Maurer R. A., Gorski J. Estrogen control of prolactin synthesis in vitro. Proc Natl Acad Sci U S A. 1978 Dec;75(12):5946–5949. doi: 10.1073/pnas.75.12.5946. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Loeb H. S., Winslow E. B., Rahimtoola S. H., Rosen K. M., Gunnar R. M. Acute hemodynamic effects of dopamine in patients with shock. Circulation. 1971 Aug;44(2):163–173. doi: 10.1161/01.cir.44.2.163. [DOI] [PubMed] [Google Scholar]
  26. MacGillivray M. H., Frohman L. A., Doe J. Metabolic clearance and production rates of human growth hormone in subjects with normal and abnormal growth. J Clin Endocrinol Metab. 1970 May;30(5):632–638. doi: 10.1210/jcem-30-5-632. [DOI] [PubMed] [Google Scholar]
  27. Malarkey W. B., Beck P. Twenty-four-hour prolactin profiles in normal and disease states: failure of thyroxine to modify prolactin secretion. J Clin Endocrinol Metab. 1975 Apr;40(4):708–712. doi: 10.1210/jcem-40-4-708. [DOI] [PubMed] [Google Scholar]
  28. Maneschi F., Navalesi R., Pilo A., Paci A. [125I]hGH metabolism in acromegaly: effects of chronic treatment with 2-Br-alpha-ergocryptine. J Clin Endocrinol Metab. 1978 Jul;47(1):110–118. doi: 10.1210/jcem-47-1-110. [DOI] [PubMed] [Google Scholar]
  29. Odell W. D., Utiger R. D., Wilber J. F., Condliffe P. G. Estimation of the secretion rate of thyrotropin in man. J Clin Invest. 1967 Jun;46(6):953–959. doi: 10.1172/JCI105601. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Onishi T., Miyai K., Izumi K., Nakanishi H., Kumahara Y. Prolactin response to chlorpromazine and thyrotropin-releasing hormone in hyperthyroidism. J Clin Endocrinol Metab. 1975 Jan;40(1):30–32. doi: 10.1210/jcem-40-1-30. [DOI] [PubMed] [Google Scholar]
  31. Parker D. C., Rossman L. G., Vander Laan E. F. Sleep-related, nychthermeral and briefly episodic variation in human plasma prolactin concentrations. J Clin Endocrinol Metab. 1973 Jun;36(6):1119–1124. doi: 10.1210/jcem-36-6-1119. [DOI] [PubMed] [Google Scholar]
  32. Perrone M. H., Hinkle P. M. Regulation of pituitary receptors for thyrotropin-releasing hormone by thyroid hormones. J Biol Chem. 1978 Jul 25;253(14):5168–5173. [PubMed] [Google Scholar]
  33. Ridgway E. C., Weintraub B. D., Cevallos J. L., Rack M. C., Maloof F. Suppression of pituitary TSH secretion in the patient with a hyperfunctioning thyroid nodule. J Clin Invest. 1973 Nov;52(11):2783–2792. doi: 10.1172/JCI107474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Ridgway E. C., Weintraub B. D., Maloof F. Metabolic clearance and production rates of human thyrotropin. J Clin Invest. 1974 Mar;53(3):895–903. doi: 10.1172/JCI107630. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Rogol A. D., Chrambach A. Radioiodinated human pituitary and amniotic fluid prolactins with preserved molecular integrity;. Endocrinology. 1975 Aug;97(2):406–417. doi: 10.1210/endo-97-2-406. [DOI] [PubMed] [Google Scholar]
  36. Rogol A. D., Rosen S. W. Prolactin of apparent large molecular size: the major immunoactive prolactin component in plasma of a patient with a pituitary tumor. J Clin Endocrinol Metab. 1974 Apr;38(4):714–717. doi: 10.1210/jcem-38-4-714. [DOI] [PubMed] [Google Scholar]
  37. Schneider A. B., Kowalski K., Sherwood L. M. "Big" human placental lactogen: disulfide-linked peptide chains. Biochem Biophys Res Commun. 1975 May 19;64(2):717–724. doi: 10.1016/0006-291x(75)90379-4. [DOI] [PubMed] [Google Scholar]
  38. Snyder P. J., Jacobs L. S., Utiger R. D., Daughaday W. H. Thyroid hormone inhibition of the prolactin response to thyrotropin-releasing hormone. J Clin Invest. 1973 Sep;52(9):2324–2329. doi: 10.1172/JCI107421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Suh H. K., Frantz A. G. Size heterogeneity of human prolactin in plasma and pituitary extracts. J Clin Endocrinol Metab. 1974 Nov;39(5):928–935. doi: 10.1210/jcem-39-5-928. [DOI] [PubMed] [Google Scholar]
  40. TAIT J. F. REVIEW: THE USE OF ISOTOPIC STEROIDS FOR THE MEASUREMENT OF PRODUCTION RATES IN VIVO. J Clin Endocrinol Metab. 1963 Dec;23:1285–1297. doi: 10.1210/jcem-23-12-1285. [DOI] [PubMed] [Google Scholar]
  41. Taylor A. L., Finster J. L., Mintz D. H. Metabolic clearance and production rates of human growth hormone. J Clin Invest. 1969 Dec;48(12):2349–2358. doi: 10.1172/JCI106201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Thompson R. G., Rodriguez A., Kowarski A., Blizzard R. M. Growth hormone: metabolic clearance rates, integrated concentrations, and production rates in normal adults and the effect of prednisone. J Clin Invest. 1972 Dec;51(12):3193–3199. doi: 10.1172/JCI107146. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Toft A. D., Boyns A. R., Cole E. N., Irvine W. J. Prolactin response to thyrotrophin releasing hormone in thyrotoxicosis. J Endocrinol. 1974 Jun;61(3):515–516. doi: 10.1677/joe.0.0610515. [DOI] [PubMed] [Google Scholar]
  44. Tsai J. S., Samuels H. H. Thyroid hormone action: stimulation of growth hormone and inhibition of prolactin secretion in cultured GH1 cells. Biochem Biophys Res Commun. 1974 Jul 10;59(1):420–428. doi: 10.1016/s0006-291x(74)80223-8. [DOI] [PubMed] [Google Scholar]
  45. Turyn D., Dellacha J. M. Specific binding of iodinated growth hormone to rat liver in vivo. Endocrinology. 1978 Oct;103(4):1190–1195. doi: 10.1210/endo-103-4-1190. [DOI] [PubMed] [Google Scholar]
  46. Vale W., Blackwell R., Grant G., Guillemin R. TRF and thyroid hormones on prolactin secretion by rat anterior pituitary cells in vitro. Endocrinology. 1973 Jul;93(1):26–33. doi: 10.1210/endo-93-1-26. [DOI] [PubMed] [Google Scholar]
  47. Wartofsky L., Dimond R. C., Noel G. L., Frantz A. G., Earll J. M. Effect of acute increases in serum triiodothyronine on TSH and prolactin responses to TRH, and estimates of pituitary stores of TSH and prolactin in normal subjects and in patients with primary hypothyroidism. J Clin Endocrinol Metab. 1976 Mar;42(3):443–458. doi: 10.1210/jcem-42-3-443. [DOI] [PubMed] [Google Scholar]
  48. Wood P. J., Shahwan M. M., Marks V. Letter: Radioimmunoassay of plasma--prolactin. Lancet. 1975 Nov 22;2(7943):1040–1041. doi: 10.1016/s0140-6736(75)90328-1. [DOI] [PubMed] [Google Scholar]
  49. Wright D. R., Goodman A. D., Trimble K. D. Studies on "big" growth hormone from human plasma and pituitary. J Clin Invest. 1974 Nov;54(5):1064–1073. doi: 10.1172/JCI107850. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Yen S. S., Ehara Y., Siler T. M. Augmentation of prolactin secretion by estrogen in hypogonadal women. J Clin Invest. 1974 Feb;53(2):652–655. doi: 10.1172/JCI107600. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Zimmerman E. A., Defendini R., Frantz A. G. Prolactin and growth hormone in patients with pituitary adenomas: a correlative study of hormone in tumor and plasma by immunoperoxidase technique and radioimmunoassay. J Clin Endocrinol Metab. 1974 Apr;38(4):577–585. doi: 10.1210/jcem-38-4-577. [DOI] [PubMed] [Google Scholar]
  52. van der Gugten A. A., Sahuleka P. C., van Galen G. H., Kwa H. G. Prolactin inhibition test with L-dopa: decrease and restoration of plasma prolactin levels in the rat by a peripheral process. J Endocrinol. 1976 Mar;68(3):369–381. doi: 10.1677/joe.0.0680369. [DOI] [PubMed] [Google Scholar]
  53. von Werder K., Clemm C. Evidence for 'big' and 'little' components of circulating immunoreactive prolactin in humans. FEBS Lett. 1974 Oct 1;47(1):181–184. doi: 10.1016/0014-5793(74)80454-0. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES